Actinium Pharmaceuticals announced new data on ATNM-400, a targeted radiotherapy showing promise in treating non-small cell lung cancer (NSCLC) with KRAS mutations and prostate cancer across PSMA expression levels. The data highlight ATNM-400's ability to overcome resistance to current EGFR- and KRAS-targeted therapies in NSCLC and its efficacy in PSMA-negative prostate cancer, addressing limitations of existing treatments. Additionally, optimized radiochemistry techniques improve the drug's tumor targeting and pharmacokinetics. These findings support ATNM-400's development as a mutation-agnostic therapy with broad solid tumor applications, with upcoming clinical studies planned.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
